Literature DB >> 8503495

Ototoxicity of erythromycin in man: electrophysiologic approach.

J A Sacristán1, M Angeles De Cos, J Soto, F Zurbano, J Pascual, A Tasis, R Valle, C De Pablos.   

Abstract

Ototoxicity is probably the least acknowledged adverse reaction of erythromycin. The mechanism of erythromycin ototoxicity is still unknown. Here we report on two new cases of erythromycin-induced hearing loss. In both of them, serial evoked auditory brainstem potentials (EABPs) were obtained. The recorded EABPs showed absence of waves I to III during treatment with erythromycin, and normalization of all EABP waves after the administration of erythromycin had been stopped. Our findings support the hypothesis that erythromycin-induced hearing loss is attributable to a functional disorder in the peripheral parts of the auditory system.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8503495

Source DB:  PubMed          Journal:  Am J Otol        ISSN: 0192-9763


  4 in total

Review 1.  Experimental, clinical and preventive aspects of ototoxicity.

Authors:  A A Chiodo; P W Alberti
Journal:  Eur Arch Otorhinolaryngol       Date:  1994       Impact factor: 2.503

Review 2.  Ototoxicity of Non-aminoglycoside Antibiotics.

Authors:  Leonard P Rybak; Vickram Ramkumar; Debashree Mukherjea
Journal:  Front Neurol       Date:  2021-03-09       Impact factor: 4.003

Review 3.  A Narrative Review of Pharmacologic Treatments for COVID-19: Safety Considerations and Ototoxicity.

Authors:  Christine Little; Maura K Cosetti
Journal:  Laryngoscope       Date:  2021-01-27       Impact factor: 2.970

4.  Macrolide-associated ototoxicity: a cross-sectional and longitudinal study to assess the association of macrolide use with tinnitus and hearing loss.

Authors:  Anna Vanoverschelde; Berthe C Oosterloo; Nelly F Ly; M Arfan Ikram; André Goedegebure; Bruno H Stricker; Lies Lahousse
Journal:  J Antimicrob Chemother       Date:  2021-09-15       Impact factor: 5.790

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.